Servizio Comunitario di Informazione in materia di Ricerca e Sviluppo - CORDIS

FP5

BIOSAFE-VACCINE-VECT Sintesi della relazione

Project ID: QLK2-CT-2001-00874
Finanziato nell'ambito di: FP5-LIFE QUALITY
Paese: Spain

A collection of vectors with different attenuation degree has been developed by modifying the sequences that regulate the expression of the different viral genes

A human vector has been developed. As intermediate steps vaccines for animal health have been developed. The vector developed could be applied to the development of vaccines for other diseases. The vaccine developed for human rotaviruses still needs to be completed and its biosafety tested in the transgenic animal model developed. Other vaccines for animal health that have been used to improve the quality and biosafety of this type of vector could be ready in 24 months. A candidate vaccine for SARS-CoV, based on a recombinant virus in which a structural gene has been deleted, is being tested in ferrets and monkeys for the moment, in collaboration with Dr. Albert Osterhaus (Rotterdam). If the results are satisfactory it may enter in preclinical trials in 1-2 years.

Informazioni correlate

Contatto

Luis ENJUANES, (Laboratory Head)
Tel.: +34-915854555
Fax: +34-915854915
E-mail